Fundació ACE
Welcome,         Profile    Billing    Logout  
 3 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rovira, Mercè Boada
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Boada, Merce
SHINE, NCT03507790 / 2022-002326-27: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
2
153
Europe, US, RoW
CT1812, Study Drug, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA)
Mild to Moderate Alzheimer's Disease
05/24
05/24
Martinez
PRO_NAT, NCT05954962: Efficacy of Micronized Natural Progesterone Vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

Recruiting
4
150
Europe
Progesterone 200 MG, Ganirelix Acetate
Instituto Bernabeu
IVF
12/24
08/25
PICS, NCT05633576: Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

Recruiting
3
40
Europe
steroid eye drops, Placebo
Radboud University Medical Center, Oogziekenhuis Rotterdam
Chronic Central Serous Chorioretinopathy
06/25
07/25
NCT06049147: Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

Completed
1
72
Europe
MBF-015 4 mg oral capsule, MBF-015 16 mg oral capsule, Placebo
Medibiofarma S.L.
Safety and Pharmacokinetic
08/23
08/23
NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma.

Completed
1
64
Europe, US
TG4050
Transgene
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
10/24
10/24
Rovira, Mercé Boada
NCT05497089 / 2022-000618-32: Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

Completed
2
203
Europe
Temelimab 54mg/kg, Placebo
GeNeuro SA, GeNeuro S.A.
Post-COVID-19 Syndrome
05/24
05/24
SToMP-AD, NCT04685590: Senolytic Therapy to Modulate the Progression of Alzheimer's Disease () Study

Active, not recruiting
2
48
Europe, US
Dasatinib + Quercetin, Placebo Capsules
Washington University School of Medicine, The University of Texas Health Science Center at San Antonio, Wake Forest University Health Sciences
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
01/28
01/29
Loh, Denissa
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
05/25
02/26
ADtouch, NCT06921759: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Not yet recruiting
3
206
Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Hand and Foot Dermatitis
07/26
09/26
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Active, not recruiting
2
17
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
NCT05960097: A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

Completed
2
675
US, RoW
CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose, CV0601 Monovalent High dose, Control vaccine, CV0801 Monovalent
GlaxoSmithKline, CureVac
SARS-CoV-2
08/24
08/24
NCT06375512: A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Active, not recruiting
1
150
US, RoW
HZ Vaccine (IN001), Placebo, Shingrix
Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
12/25
06/26
DehydraTECH, NCT06648031: Comparison of the Safety, Efficacy and Pharmacokinetics of -CBD and -GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Recruiting
1
80
RoW
Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide
Lexaria Bioscience Corp.
Type2diabetes
05/25
09/25
Forcelini, Cassiano Mateus
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
Hanta, Cezara Roxana
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rovira, Mercè Boada
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Boada, Merce
SHINE, NCT03507790 / 2022-002326-27: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
2
153
Europe, US, RoW
CT1812, Study Drug, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA)
Mild to Moderate Alzheimer's Disease
05/24
05/24
Martinez
PRO_NAT, NCT05954962: Efficacy of Micronized Natural Progesterone Vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

Recruiting
4
150
Europe
Progesterone 200 MG, Ganirelix Acetate
Instituto Bernabeu
IVF
12/24
08/25
PICS, NCT05633576: Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

Recruiting
3
40
Europe
steroid eye drops, Placebo
Radboud University Medical Center, Oogziekenhuis Rotterdam
Chronic Central Serous Chorioretinopathy
06/25
07/25
NCT06049147: Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

Completed
1
72
Europe
MBF-015 4 mg oral capsule, MBF-015 16 mg oral capsule, Placebo
Medibiofarma S.L.
Safety and Pharmacokinetic
08/23
08/23
NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma.

Completed
1
64
Europe, US
TG4050
Transgene
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
10/24
10/24
Rovira, Mercé Boada
NCT05497089 / 2022-000618-32: Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

Completed
2
203
Europe
Temelimab 54mg/kg, Placebo
GeNeuro SA, GeNeuro S.A.
Post-COVID-19 Syndrome
05/24
05/24
SToMP-AD, NCT04685590: Senolytic Therapy to Modulate the Progression of Alzheimer's Disease () Study

Active, not recruiting
2
48
Europe, US
Dasatinib + Quercetin, Placebo Capsules
Washington University School of Medicine, The University of Texas Health Science Center at San Antonio, Wake Forest University Health Sciences
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
01/28
01/29
Loh, Denissa
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
05/25
02/26
ADtouch, NCT06921759: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Not yet recruiting
3
206
Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Hand and Foot Dermatitis
07/26
09/26
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Active, not recruiting
2
17
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
NCT05960097: A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

Completed
2
675
US, RoW
CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose, CV0601 Monovalent High dose, Control vaccine, CV0801 Monovalent
GlaxoSmithKline, CureVac
SARS-CoV-2
08/24
08/24
NCT06375512: A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Active, not recruiting
1
150
US, RoW
HZ Vaccine (IN001), Placebo, Shingrix
Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
12/25
06/26
DehydraTECH, NCT06648031: Comparison of the Safety, Efficacy and Pharmacokinetics of -CBD and -GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Recruiting
1
80
RoW
Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide
Lexaria Bioscience Corp.
Type2diabetes
05/25
09/25
Forcelini, Cassiano Mateus
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting
4
2076
Europe, Canada, US, RoW
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance
Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Motor Function, Cognitive Function, Contrast Media
12/28
12/28
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
Hanta, Cezara Roxana
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27

Download Options